前列腺癌内分泌治疗的生存随访  

Androgen deprivation therapy for prostate cancer: A follow-up study of the patients' survival time

作　　者：张世革[1] 王久林[1] 吴烨[1] 邵宁[1] 乔迪[1] 丁毅[1] 

机构地区：[1]江苏省老年医院泌尿外科,江苏南京210024

出　　处：《中华男科学杂志》2013年第12期1103-1106,共4页National Journal of Andrology

摘　　要：目的:探讨前列腺癌内分泌治疗后患者长期生存情况及相关预后因素。方法:随访124例前列腺癌内分泌治疗后的生存情况,用Kaplan-Meiers生存分析比较不同分型患者的生存时间情况。结果:全组前列腺癌有效随访者平均生存时间为5.912年,中位生存时间为7.81年。按前列腺癌诊断时的特征情况分组分析后仅发现临床未有骨转移者的生存时间相比有骨转移的患者较长(P=0.04)。而不同病理分型和前列腺特异性抗原(PSA)水平对内分泌治疗的预后无显著影响。对58例已死亡的患者分析显示,前列腺癌相关死亡的35例患者生存时间于其他死因患者的生存时间相比并无显著差异(P=0.499)。结论:前列腺癌有无骨转移可能是影响晚期前列腺癌预后的重要因素,其比病理分级情况对生存时间的影响更为显著。Objective： To explore the long-term survival and prognosis of prostate cancer patients after treated by androgen dep- rivation therapy. Methods： We conducted a follow-up study of 124 patients with prostate cancer treated by androgen deprivation ther- apy, and compared the survival times of the patients with different pathological grades and clinical characteristics using Kaplan-Meiers survival curves. Results： The mean survival time of the 124 patients after androgen deprivation therapy was 5. 912 years, with the median survival time of 7.81 years. The patients with bone metastases showed a shorter survival time than those with non-bone metasta- sis （P = 0.04）. Pathological grades and PSA levels were not prognostic factors. No significant differences were found in the mean survival time between those died of prostate cancer （ n = 35） and those from other factors （ n = 23） （P = O. 50）. Conclusion ： Bone metastasis is an important prognostic factor in advanced prostate cancer following androgen deprivation therapy, which is more signifi- cantly correlated with the survival time of the patients than tumor grades and clinical classification.

关 键 词：前列腺癌 内分泌治疗 生存期 

分 类 号：R737.25[医药卫生—肿瘤]